Navigation Links
First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Date:12/12/2007

data-sets have been transferred and the authorities have confirmed the receipt and navigability of the information. Both the rolling NDA and the electronic format could greatly facilitate the review process.

The first modules of the NDA package are ready and will be filed before year-end 2007. The remaining modules are expected to be transferred and filing is forecast to be completed by the end of February 2008.

Dr Khalid Islam, President and CEO of Arpida Ltd., commented: "We are pleased with the progress made across the several different programmes.

Firstly, initiation of patient enrolment in the Phase II trial with intravenous iclaprim in HAP/VAP/HCAP provides a good basis for the completion of the trial within the planned timelines. HAP/VAP/HCAP is a serious, life-threatening condition with a high medical need. We believe that iclaprim could have a high potential in this indication based on its potent and bactericidal action on MRSA and its good distribution in those lung compartments where the key respiratory pathogens reside."

Dr Islam added: "Moreover, we are very pleased with the results of the ascending dose trial with oral iclaprim, which show a good tolerability at high doses. We are now working to complete the Phase I programme while at the same time discussing with the regulatory authorities regarding the potential next steps in the development path of oral iclaprim.

Work on the NDA for intravenous iclaprim in cSSSI is progressing well. We expect to file the first modules of the package before year-end and complete the filing by the end of February 2008. After finalising the NDA filing, our next steps will focus on the preparation of the commercial launch of iclaprim."

Conference Call

Arpida will host a conference call to discuss these recent developments, today, 11 December 2007, at 3 pm CET. The dial-in numbers are:

+41-(0)91-610-56-00 (Europe)

+44-(0)207-107-06-11 (UK)

+1-(1)866-29
'/>"/>

SOURCE Arpida Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Niagara Thermal Products is proud to announce that ... ("B3") as the critical thermal component supplier in support ... Corps of Engineers.  B3 has developed the only comprehensive ... destroys VOCs and other chemical pollutants, allergens and organic ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 ... Almshouse Road, Warrington, Pa. , Details: The Hepatitis ... finding a cure for hepatitis B and improving the quality ... Crystal Ball on Friday, April 11 at Warrington Country Club ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... Co-founder Recognized for Role in Engineering Microbes to Produce ... TR35 2007 Recipients to be Honored at Technology Review,s Emerging ... ... Amyris Biotechnologies is,pleased to announce that Neil Renninger, Ph.D., co-founder ...
... 13 PharmAthene, Inc.,(Amex: PIP ) a ... and chemical threats, announced today,that proceedings have been ... validity of the merger between Healthcare Acquisition Corp. ... Chancery will determine that the Merger was,validly approved ...
... BioVex Inc, a biotechnology,company developing clinical stage treatments ... today that it has appointed Dr. Thaddeus,Pullano, 53, ... http://www.newscom.com/cgi-bin/prnh/20070815/NYW022 ) Previously, Dr. Pullano ... Acambis from 2003 to 2007. In this role, ...
Cached Biology Technology:Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Review's Prestigious TR35 List of Top Young Innovators 2Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Review's Prestigious TR35 List of Top Young Innovators 3Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court 2BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance 2
(Date:7/9/2014)... JOLLA-The ability to switch out one gene for another ... crossed from science fiction to reality within this decade. ... both promise--the hope of fixing disease-causing genes in humans, ... Salk scientists have put one of those concerns to ... the overall occurrence of mutations in the cells. The ...
(Date:7/9/2014)... - Regulated deer hunts in Indiana state parks have ... of damage caused by overabundant populations of white-tailed deer, ... by Michael Jenkins, associate professor of forest ecology, found ... of organizing hunts in state parks has successfully spurred ... rendered scarce by browsing deer. , Jenkins said ...
(Date:7/9/2014)... Scientists from the Spanish National Cancer Research Centre (CNIO) ... stem cells, also regulates cell division in stratified epitheliathose ... or cover the oesophagus or the vaginain adult organisms. ... the journal Nature Communications , this factor could ... derived from stratified epithelia of the oesophagus and skin. ...
Breaking Biology News(10 mins):No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Hunting gives deer-damaged forests in state parks a shot at recovery 2CNIO scientists discover that pluripotency factor NANOG is also active in adult organisms 2
... to Josef Ackermann, the head of Deutsche Bank. At almost ... in Rome. The hand of the manager in charge of ... or security staff have had to conduct painstaking inspections of ... approach. At the end of 2011, though, the scanner T-Cognition ...
... release is available in German . ... from Siegen and Professor Jacek Błażewicz from Poznan have ... (DFG, German Research Foundation) and the Foundation for Polish ... scientific collaboration. "The two researchers perform outstanding research, are ...
... groundbreaking new gene sequencing technology, researchers have demonstrated that ... Acute Myeloid Leukemia, AML, one of the most common ... Pacific Biosciences, allows for the rapid and comprehensive detection ... findings, published online April 15 in Nature , ...
Cached Biology News:On the safe side: Contact-free analysis of chemical substances 2Copernicus Award 2012 for German-Polish collaboration in business information systems 2Copernicus Award 2012 for German-Polish collaboration in business information systems 3Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia 2
Adhesive seal-tab, for HybriWell™ hybridization sealing system *set of 400*...
... cell culture systems provide an integrated ... staining and imaging. Each system uses ... optical-quality coverslips in cell culture plates. ... and ready to use. Individual chambered ...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
RECOMBINANT EQUINE TNF ALPHA Product Type: Recombinant Protein...
Biology Products: